What you should know about continuing bisphosphonate osteoporosis medications.

What we don't know about osteoporosis.

Bone remodeling Our current understanding is that postmenopausal osteoporosis results from a bone remodeling imbalance with bone resorption exceeding bone formation and that the medications approved for osteoporosis treatment all work by modulating bone remodeling in a favorable way. This is almost certainly correct, yet there is much more to be learned about bone remodeling that might enhance ...

Atraumatic bilateral femur fracture in long-term bisphosphonate use.

Postmenopausal women with osteoporosis are commonly treated with the bisphosphonate class of medications, one of the most frequently prescribed medications in the United States. In the past 4 years, reports have been published implying that long-term bisphosphonate therapy could be linked to atraumatic femoral diaphyseal fractures. This article presents a case of a 67-year-old woman who present...

What do we know about atypical femoral fractures? Insights and enigmas.

Although the existence of atypical femoral fractures is well established and bisphosphonate therapy is thought to be a major risk factor, the underlying mechanisms are poorly understood. Epidemiological data show that atypical femoral fractures account for only a small proportion of diaphyseal subtrochanteric femoral fractures, being about 100 times less common than proximal femoral fractures. ...

What you need to know about ... osteoporosis.

Presenting a Hybrid Approach based on Two-stage Data Envelopment Analysis to Evaluating Organization Productivity

   Measuring the performance of a production system has been an important task in management for purposes of control, planning, etc. Lord Kelvin said :“When you can measure what you are speaking about, and express it in numbers, you know something about it; but when you cannot measure it, when you cannot express it in numbers, your knowledge is of a meager and unsatisfactory kind.” Hence, manag...